Last reviewed · How we verify
Vancomycin II
Vancomycin II inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption.
Vancomycin II inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption. Used for Serious gram-positive bacterial infections including methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile-associated diarrhea, Endocarditis.
At a glance
| Generic name | Vancomycin II |
|---|---|
| Also known as | glycopeptide antibiotic |
| Sponsor | Wake Forest University Health Sciences |
| Drug class | Glycopeptide antibiotic |
| Target | D-Ala-D-Ala peptidoglycan precursor |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Vancomycin II is a glycopeptide antibiotic that targets the bacterial peptidoglycan layer, a critical structural component of gram-positive bacterial cell walls. By binding to D-alanyl-D-alanine residues on peptidoglycan precursors, it prevents the cross-linking reactions necessary for cell wall integrity. This leads to cell wall instability, leakage of cellular contents, and bacterial cell death.
Approved indications
- Serious gram-positive bacterial infections including methicillin-resistant Staphylococcus aureus (MRSA)
- Clostridium difficile-associated diarrhea
- Endocarditis
- Sepsis caused by susceptible gram-positive organisms
Common side effects
- Nephrotoxicity
- Ototoxicity
- Red man syndrome (flushing, pruritus)
- Phlebitis at infusion site
- Fever
- Thrombocytopenia
Key clinical trials
- Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients (PHASE1, PHASE2)
- Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers (PHASE2)
- Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders (PHASE2)
- Maternal Probiotic Intervention to Improve Gut Health - Trial II - Bangladesh (PHASE2)
- Combination Study of Antibiotics With Enzalutamide (PROMIZE) (PHASE1, PHASE2)
- Maternal Probiotic Intervention to Improve Gut Health - Trial II - Burkina Faso (MPIGH-II) (PHASE2)
- PMT for MDRO Decolonization (PHASE2)
- Maternal Probiotic Intervention to Improve Gut Health-Trial II-Pakistan (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vancomycin II CI brief — competitive landscape report
- Vancomycin II updates RSS · CI watch RSS
- Wake Forest University Health Sciences portfolio CI